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Similar biotherapeutic products (SBPs) or biosimilars are biologics developed by pharmaceutical
manufacturers to match originator biologics that have been on the market for a long time and lost their
exclusivity (patent and market protection). The recently issued WHO guidelines on evaluation of SBPs
provide clear guidance for manufacturers and regulators on how to develop and gain approval for these
products.
The present contribution illustrates the rationale for and general principles of the clinical programs
used in the development of SBPs, taking the example of the three biosimilar products developed and
marketed in Europe by Sandoz, namely growth hormone (Omnitrope, the ﬁrst ever EU biosimilar
approval), erythropoietin a (Binocrit), and ﬁlgrastim (Zarzio).
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Following the patent expiries of the ﬁrst biotechnology-derived
therapeutic proteins, off-patent biopharmaceuticals in general are
becoming an increasingly attractive target for pharmaceutical
companies. In contrast to “standard” small-molecule chemical
drugs, biopharmaceuticals are considerably larger and more
complex molecules, more difﬁcult to characterize and produced
from living organisms. Due to this complexity and to the inherent
variability of biologics manufacturing, the generic pathway for
regulatory approval cannot be used for these so-called Similar
Biotherapeutic Products (SBPs) or biosimilars. In Europe, a regula-
tory pathway for the approval of biosimilar products has been
developed and effectively implemented in recent years. Clear
guidance has also been given with regard to the data needed to
demonstrate the similar nature of the similar biological medicinal
product to the reference product in terms of quality, safety, and
efﬁcacy [1e7]. Other countries including Canada, Japan, and the
USA have now also adopted abbreviated regulatory pathways for
approval of biosimilar products, relying on information in the
public domain regarding the off-patent reference biologics (safety,
dosing, efﬁcacy, mechanism of action, etc.). In October 2009, the
WHO Expert Committee on Biological Standardization issued
guidelines on the evaluation of SBPs to promote globally accepted0.
ll rights reserved. The World Healthnorms and standards for the evaluation of these products by
regulatory agencies [8]. In a recent workshop which was jointly
held by Korea FDA and WHO in Seoul 2010, ﬁrst experience on the
implementation of these guidelines was reviewed. The present
contribution describes the general principles and rationale used in
clinical programs for the development of SBPs with special refer-
ence to the three biosimilar products developed and marketed in
Europe by Sandoz, i.e., growth hormone (Omnitrope, the ﬁrst ever
biosimilar EU approval), erythropoietin a (Binocrit), and ﬁlgrastim
(Zarzio).
2. General principles of clinical development of similar
biotherapeutic products
Prior to proceeding to clinical studies, SBPs will have been
extensively characterized in an iterative process to closely match the
reference biotherapeutic product (RBP) (Fig. 1). The comparability
exercises follow the same principles as those used for establishing
comparability of originator biologics after changes inmanufacturing.
Manufacturers of biologics frequently make changes to the
manufacturing processes of their products both during development
and after approval [9]. Ample guidance exists regarding compara-
bility exercises both for biotechnology-derived therapeutic proteins
and for development of biosimilars [2,9]. Often non-inferiority
designs have been used in the clinical comparability studies of
originator molecules.
In general, the clinical program for SBP development will consist
of studies to demonstrate a comparable pharmacokinetic (PK) andOrganization has granted the Publisher permission for the reproduction of this article.
Table 1
Number of clinical studies and total number of subjects in the clinical development
programs of Sandoz SBPs.
Product PK/PD studies Pre-marketing efﬁcacy/
safety studies
No. subjects No. studies No. subjects No. studies
Omnitrope 133 5 210 5
Binocrit 234 5 593 2
Zarzio 146 4a 170 1
a Two studies with a total of 80 subjects have been designed to demonstrate
comparable efﬁcacy using ANC as primary surrogate parameter of efﬁcacy.
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often be in healthy volunteers, and are typically in crossover
designs, which are useful and highly sensitive designs to detect any
differences between the RBP and SBPs [10]. Once PK/PD compara-
bility has been established comparative safety and efﬁcacy studies
will follow to ultimately conﬁrm therapeutic similarity. The
conﬁrmation of a comparable proﬁle in the PK/PD studies will
justify the same posology of SBP and RBP. No additional dose
ﬁnding studies are needed. Comparative efﬁcacy and safety is best
demonstrated in head-to-head studies in a study population that is
sufﬁciently sensitive to detect differences between the products, if
such differences exist. In the WHO guidelines, equivalence study
designs (requiring lower and upper comparability margins) are
preferably recommended for the comparison of efﬁcacy and safety
of SBP with RBP. However, non-inferiority designs may also be used
to demonstrate clinically relevant comparability. It is not to be
expected that the SBP will be inferior or superior to the RBP if
physicochemical, biological, non-clinical, and PK/PD comparability
has been proven. While the non-inferiority margin is negotiated
with the regulatory authority, the basis for the non-inferiority
assessment will be the lower 1-sided 95% conﬁdence interval
(95% CI) for the difference between treatments, which represents
a lower boundary for the difference.
Finally, conclusion of biosimilarity will be provided by the
totality of evidence (e.g., quality, non-clinical, and clinical data).
3. Examples of approved biosimilars developed by Sandoz
During the workshop in Seoul 2010, the general principles and
rationale for the clinical development programs of SBPs were
illustrated by the examples of the development programs for
Omnitrope, Binocrit, and Zarzio. The total number of clinical
studies and subjects involved in the clinical programs for conﬁr-
mation of comparability with the reference originator product are
summarized in Table 1.
3.1. Recombinant human growth hormone - Omnitrope
In 2006, Sandoz received the ﬁrst centralized biosimilar market
authorization in the EU for its recombinant human growth
hormone (rhGH), Omnitrope [11]. Omnitrope (somatropin) is
also approved in other countries and regions including the US,Fig. 1. Biosimilars are systematically engineered to match the reference product.Canada, Japan, Australia, Mexico, and Argentina. The reference
product was Genotropin, the recombinant human growth
hormone of Pﬁzer (formerly Pharmacia) originally authorized in
Europe in 1988. A similar pharmacokinetic and pharmacodynamic
proﬁle of Omnitrope and Genotropin was demonstrated in
randomized, double-blind, single-dose, crossover PK/PD studies in
healthy volunteers. In these studies, endogenous GH secretion was
equally suppressed with a 25 h continuous i.v. infusion of octreo-
tide (40 mg/h) starting 1 h before rhGH administration [12,13].
Comparable therapeutic efﬁcacy between Omnitrope and the
reference product Genotropin was demonstrated in a head-to-
head study of rhGH treatment in 89 short children due to growth
hormone deﬁciency [14,15]. Growth hormone treatment will result
in a rapid and marked increase of longitudinal growth velocity in
GH-deﬁcient children (so-called catch-up growth) [14]. After nine
months, the baseline-adjusted difference between Omnitrope and
Genotropin in mean height velocity (HV) was 0.19 cm/yr (95%
conﬁdence interval (CI) [e1.34; 0.95]) and in mean height velocity
standard deviation score (HVSDS) was 0.79 (95%CI [e0.56; 2.15]).
There were no clinically relevant differences between treatments at
any time point, thus showing comparable efﬁcacy across all treat-
ment groups. Clinical comparability in terms of safety and immu-
nogenicity between Omnitrope and Genotropin was also
conﬁrmed [11,14,15]. Switching rhGH preparations (Genotropin
lyophilizate to Omnitrope liquid and Omnitrope lyophilizate to
Omnitrope liquid) was well tolerated and safe. Long-term efﬁcacy
and safety of Omnitrope treatment has been demonstrated [11,15].3.2. Recombinant erythropoietin a e Binocrit
Binocrit was developed using the reference product, Eprex/
Erypo, the JansseneCilag recombinant erythropoietin a autho-
rized in the EU in 1994 [16]. A similar pharmacokinetic and phar-
macodynamic proﬁle of Binocrit and the reference product was
demonstrated in comparative PK/PD studies in healthy volunteers
for i.v. and s.c. routes of administration [16e19]. Comparable efﬁ-
cacy was conﬁrmed in treatment of anemia by administration of i.v.
erythropoietin a in 478 chronic renal failure patients receiving
hemodialysis [20]. Patients with hemoglobin (Hb) levels of
10.0e13.0 g/dl were randomized to either continue their current i.v.
erythropoietin a treatment or switch to Binocrit. During treat-
ment, erythropoietin a dosageswere titrated tomaintain Hb values.
The primary endpoint was the difference between treatment
groups in the mean absolute change of Hb levels between baseline
and evaluation period (weeks 25e28). Mean changes in Hb levels
were 0.15  0.09 g/dl in the Binocrit and 0.06  0.12 g/dl in the
comparator group. The difference between groups in the per
protocol population of 325 patients was 0.08 g/dl Hb (95% CI [e0.17;
0.34]), well within the predeﬁned equivalence margin of 0.5 g/dl
Hb for demonstration of comparable efﬁcacy. Comparability was
also demonstrated in the intention-to-treat (ITT) population of 465
patients with a difference in Hb change between groups of 0.19 g/dl
Table 2
Clinical pharmacodynamic and pharmacokinetic studies comparing Zarzio and Neupogen in healthy volunteers.
Study EP06-101 EP06-102 EP06-103 EP06-105
Design Randomized, double-blind,
2-way crossover
Randomized, double-blind,
2-way crossover
Randomized, double-blind,
2-way crossover, 2 dose groups
Randomized, double-blind,
2-way crossover
No. of subjects 40 26 56 24
Age (range), gender 25e45 years, 53% male 23e39 years 54% male 21e54 years 59% male 21e53 years 54% male
Dose 10 mg/kg 5 mg/kg 2.5 or 5 mg/kg 1 mg/kg
Frequency of dosing Daily s.c. injections for 7 days Single i.v. injection Daily s.c. injections for 7 days Single s.c. injection
Objectives Primary: PK bioequivalence
Secondary: PD, safety,
local tolerance
Primary: PK bioequivalence
Secondary: PD, safety
Primary: PD equivalence
Secondary: PK, safety,
local tolerance
Primary: PD equivalence
Secondary: PK, safety, local
tolerance
A. Berghout / Biologicals 39 (2011) 293e296 295Hb (95% CI [e0.04; 0.42]). Hb levels and erythropoietin a dosages
remained stable throughout the entire study period of 56 weeks.
The long-term safety proﬁle of Binocrit was similar to that of the
comparator Eprex/Erypo [20].
In addition, a randomized, multicentre, double-blind study was
performed in 114 cancer patients using the s.c. route of adminis-
tration to evaluate the efﬁcacy and safety of Binocrit in the
treatment of chemotherapy associated anemia [21].
3.3. Recombinant ﬁlgrastim - Zarzio
Zarziowas developed using the reference product Neupogen,
the Amgen recombinant ﬁlgrastim authorized in the EU in 1995
[22,23]. The clinical program to conﬁrm comparable efﬁcacy and
safety consisted of four PK/PD studies in healthy volunteers
comparing pharmacokinetic and pharmacodynamic/efﬁcacy prop-
erties of both products as well as a single-arm phase III study using
Zarzio for primary prophylaxis of severe neutropenia in chemo-
therapy-naïve breast cancer patients treated with doxorubicin and
docetaxel chemotherapy (Tables 1 and 2).
Studies in healthy subjects are very sensitive to differences
because the number of G-CSF receptors is higher and the bone
marrowismore responsive than inneutropeniapatientsundergoing
cytotoxic chemotherapy. Comparable efﬁcacy of Zarzio and Neu-
pogen was conﬁrmed based on the pharmacodynamic data in
healthy volunteers receiving daily ﬁlgrastim s.c. injections over
a period of seven days. Absolute neutrophil count (ANC)was used as
the usual relevant parameter for pharmacodynamic (PD) response
[22,24]. Primary PD parameterswere ANC peak response (Emax) and
ANC exposure, i.e. the area under the effect curve (AUEC) over 10
days. The boundaries to establish comparability were deﬁned a pri-
ori considering 15% of the PD response reported for Neupogen
comparedwith placebo as the smallest clinically relevant difference
in PD responsebetween the test and referenceproduct. The absolute
neutrophil count (ANC) curves were shown to be similar whatever
the route and dose. The dose response curves of both products were
comparable. The difference in PD response between both products
was well within the predeﬁned boundaries for comparability even
after lowering the margin from 15% to 10% demonstrating compa-
rability of efﬁcacy [22]. The time proﬁle of CD34þ cell counts as
a secondary PD parameter useful for evaluating stem cell mobili-
zation was also similar for both products.
Comparable pharmacokinetics between Zarzio and Neu-
pogen have also been shown [22]. Pharmacokinetics of ﬁlgrastim
are complex and non-linear due to the receptor-mediated drug
clearance resulting from the saturable drug capture by the G-CSF
receptor and the stimulation of this receptor by ﬁlgrastim, which is
time and dose dependent. The difference in elimination charac-
teristics at different doses is related to the fact that receptor-
mediated clearance (which is saturable) is predominant at lower
doses, while renal clearance becomes more important at higher
doses relative to the amount of receptors. Moreover, in a populationwhere the amount of receptors relative to the administered drug
will be low, i.e. in neutropenia patients (the target population),
renal clearance will prevail and signiﬁcant differences in PD
response are not to be expected as PD response is related to the
amount of G-CSF bound to its target cells [22].
Direct comparison in healthy volunteers conﬁrmed compara-
bility in terms of safety between Zarzio and Neupogen. The
single-arm phase III study using Zarzio for primary prophylaxis of
severe chemotherapy-induced neutropenia in breast cancer
patients provided supportive evidence of efﬁcacy, safety, tolera-
bility and immunogenicity of ﬁlgrastim [24].
4. Conclusion
The clinical development of the three biosimilar products
developed and marketed in Europe by Sandoz, namely growth
hormone (Omnitrope), erythropoietin a (Binocrit), and ﬁlgrastim
(Zarzio) are excellent examples to illustrate the general principles
of the clinical programs for the development of SBPs. Prior to the
start of clinical comparability studies developers of SBPs will have
extensively characterized their biosimilar product in an iterative
process to establish similarity with the comparator product at the
physicochemical, biological and non-clinical level. If comparability
has been established at all these levels, it is not to be expected that
the SBP will be inferior or superior to the RBP and non-inferiority
designs may be used to demonstrate clinically relevant compara-
bility. Conclusion of biosimilarity will ﬁnally be provided by the
totality of evidence (e.g., quality, non-clinical, and clinical data).
The recently issued WHO guidelines on evaluation of SBPs
provide clear guidance for manufacturers and regulators on how to
develop and gain approval of these products. They also constitute
a valuable basis for the development of the next wave of more
complex SBPs such as monoclonal antibodies.
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